Lung Cancer is basically a matter of grave concern! According to Globacon 2018, the incidence of Lung cancer is increased up to 11 percent!
Initiated by Dr. Anita Ramesh of Freedom from Cancer a Trust that has been actively associated with the act of championing the cause of cancer, Lung Cancer Symposium 2019 was held at Hotel Rain Tree, Teynampet. 5 Sessions that discussed & deliberated on the contemporary trends & treatment methodologies, were held with each Session involving a team of panellists & each of them coming up with references & remarks pertaining to the aspects of treatment of cancer. While well known specialists stood & served as Moderators, the panellists consisted of renowned cancer specialists.
Dr. Anita Ramesh set the scenario to roll by a formal introduction while she moderated Session 2 too!
Session 1 was about the Role of CVAD in Oncology & Dr. Purvish Parikh was the Moderator. The Session discussed & deliberated on Chemotherapy & the role play of Oncologists at that time. With Chemotherapy still remaining one of the modalities of sole treatment for mutation driver negative cancer, the session also touched on the subject of delegation of the administration of Chemotherapy. Costs, Convenience, Care & Suitability of the Mode of Treatment were also touched upon. Mention was also made on the use of targeted drugs & combination of chemotherapy may become the standard of care in cure as it has shown more prolongation of life. It also stressed on the need for training to treat.
Session 2 which was about the Evolution keeping pace with today’s approaches to Molecular Diagnosis & Multi Disciplinary Management of NSCLC. Moderated by Dr. Anita Ramesh, it threw light on the role play of Radiologists, Molecular Markers, Relapse, Resistance, Rebiopsy, Osimertimib which is effective for relapsed cases etc.
Session 3 discussed about Strengthening the Management of First Line EGFR NSCLC. Dr. Anjana Goel was the Moderator & the panellists talked about Lung Cancer Mutation Consortium also referring to news published in The New England Journal of Medicine. The aspect of Optimal Sequence for EGFR Sequence for Mutation was also touched upon besides Targeted Therapy with Oral Tablets in treatment of lung cancer for mutation positive diseases.
Dr. Maurice Perol from Lyon, the 2nd largest city in France who is employed at Leon Berard Cancer Centre moderated Session 4 which was on Clinical Experience ofOsimertinib in First Line EGFR, giving references & remarks in detail & in depth about the prevailing trends throughout the world pertaining to EGFR Mutations & its Variations as well. The roles of Re-Biopsy & Liquid Biopsy were also dealt with. Treatment Strategies, 1st Line Treatment & Resistance Mechanism etc were also discussed.
The concluding Session 5 moderated by Dr. T.Raja was a Case Based Panel Discussion which touched upon subjects as Biomarker Testing, Initial Diagnostic Testing, Molecular Testing etc.
Immunotherapy which is a highly talked of subject that is needed in few patients with PD1 expressed moderate & high tumour, was also discussed. The need to discuss on expensive treatment modalities with the patients concerned was also deliberated in detail.
About 120 Delegates & Faculties from Chennai & all over Tamilnadu participated besides Dr. Maurice Perol from France.
